Pretherapeutic evaluation of cytokeratin fragment 19 (CYFRA 21-1) in 240 patients with lung cancer in comparison to carcinoembryonic antigen (CEA), neuron-specific enolase (NSE), squamous cell carcinoma antigen (SCC-Ag), tissue polypeptide antigen (TPA) and tissue polypeptide specific antigens (TPS)

Tumor Diagnostik und Therapie

Volumn 18, Issue 1, 1997, Pages 14-19

  Scheulen, M E ^a   Klanig, H ^a   Wiefelsputz J K ^a   Kamper P ^a   Wagner, B ^b   Konietzko, N ^b   Seeber, S ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b RUHRLANDKLINIK   (Germany)

Author keywords

CEA; CYFRA 21 1; lung cancer; NSE; SCC Ag; TPA; TPS

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19 FRAGMENT; CYTOKERATIN FRAGMENT 19; NEURON SPECIFIC ENOLASE; TISSUE POLYPEPTIDE ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY;

EID: 0031009915     PISSN: 0722219X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Beahrs O H. Henson D E, Hutter R V P. Myers M H (eds.): American Joint Committee on Cancer: Manual for Staging of Cancer. J B Lippincott, Philadelphia, 3rd Ed., 1988
2. Body J J, Sculier J P, Raymakers N. Paesmans M. Ravez P, Libert P. Richez M, Dabouis G. Lacroix H, Bureau C, Rhiriaux J, Lecomte J, Brohée D, Mommen P, Frühling J, Klastersky J: Evaluation of squamous cell carcinoma antigen as a new marker for Jung cancer. Cancer 65 (1990) 1552-1556
3. Björklund B, Einarson R: TPS (tissue polypeptide specific antigen) in oncologic practice: a review with reference to 3000 cases of breast cancer. Tumordiagn. Ther. 17 (1996) 67-73
4. Buccheri C F, Ferrigno D, Sartoris A M, Violante V, Vola F, Curcio A: Tumor markers in bronchogenic carcinoma. Superiority of tissue polypeptide antigen to carcinoembryonic antigen and carbohydrate antigenic determinant 19-9. Cancer 60 (1987) 42-50
5. Dent P B, McCulloch P B, Wesley-James O, MacLaren R, Muirhead W, Dunnett C W: Measurement of carcinoembryonic antigen in patients with bronchogenic carcinoma. Cancer 42 (1978) 1484-1491
6. Eberhardt W, Wilke H, Stamatis G, Krause B, Stuschke M, Stahl M, Müller M R. Schlenger L, Trenn G, Nowrousian M R, Greschuchna D, Konietzko N, Seeber S: Intensive preoperative chemo-radiotherapy including hyperfractionated accelerated radiotherapy for locally far advanced NSCLC, Lung Cancer 11, Suppl. 1(1994) 184
7. Ebert W, Leichtweis B, Schapöhler B, Muley T: The new tumor marker CYFRA is superior to SCC antigen and CEA in the primary diagnosis of lung cancer. Tumordiagn. Ther. 14 (1993) 91-99
8. Ebert W, Dienemann H, Fateh-Moghadam A, Scheulen M, Konietzko N, Schleich T, Bombardieri E: Cytokeratin 19 fragment CYFRA 21-1 compared with carcinoembryonic antigen, squamous cell carcinoma antigen and neuron-specific enolase in lung cancer. Results of an international multicentre study. Eur. J. Clin. Chem. Clin. Biochem. 32 (1994) 189-199
9. Fischbach W, Rink C: SCC-Antigen: ein sensitiver und spezifischer Tumormarker für Plattenepithelkarzinome? Dtsch. Med. Wochenschr. 113 (1988) 289-293
10. Hanley J A, McNeil B J: The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 43 (1982) 29-36
11. Kruskal W H: A nonparametric test for the several sample problem. Ann. Math. Stat. 23 (1952) 525-540
12. Lüthgens M, Schlegel G: Verlaufskontrolle bei Bronchialkarzinomen mit Tissue Polypeptide Antigen und Carcinoembryonalem Antigen. Tumordiagn. Ther. 6 (1985) 1-7
13. Mann H B. Whitney P R: On a test of whether one of two random variables is stochastically larger than the other. Ann. Math. Stat. 18 (1974) 50-60
14. Martini N, Kris M G, Flehinger B J, Gralla R J, Bains M S, Burt M E, Heelan R, McCormack P M, Pisters K M W, Rigas J R. Rusch V W, Ginsberg R J: Preoperative chemotherapy for stage IIIa (N2) lung cancer: the Sloan-Kettering experience with 136 patients. Ann. Thorac. Surg. 55 (1993) 1365-1374
15. Pujol J-L, Grenier J, Daurès J-P. Daver A. Pujol H, Michel F-B: Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer. Cancer Res. 53 (1993) 61-66
16. Rastel D, Ramaioli A, Cornillie F, Thirion B, on behalf of the CYFRA 21-1Multicentre Study Group: CYFRA 21-1, a sensitive and specific new tumour marker for squamous cell lung cancer. Report of the first European multicentre evaluation. Eur. J. Cancer 30A (1994) 601-606
17. Rosell R, Gómez-Codina J, Camps C, Maestre J, Padille J, Cantó A. Mate J L, Li S. Roig J, Olazabal A, Canela M, Ariza A, Skacel Z, Morera-Prat J, Abad A: A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. New Engl. J. Med. 330 (1994) 153-158
18. Rusch V W, Albain K S, Crowley J J, Rice T W, Lochyna V, McKenna R Jr., Livingston R B, Griffin B R. Benfield J R: Surgical resection of stage IIIA and IIIB non-small-cell lung cancer after concurrent induction chemotherapy. J. Thorac. Cardiovasc. Surg. 105 (1993) 97-106
19. Scheulen M E: Welche Tumormarker sind für die Krebsnachsorge von praktischer Bedeutung? Münch. Med. Wochenschr. 132 (1990) 240-245
20. Scheulen M E, Eberhardt W, Klanig H, Krause B, Wilke H, Wiefelspütz J K, Kamper P. Seeber S: CYFRA 21-1 in the followup of patients with localiy advanced non-small-cell lung cancer during and after neoadjuvant chemo-radiotherapy and surgery. Tumordiagn. Ther. 17 (1997) 20-28
21. Spearman C: The proof and measurement of association between two things. Amen. J. Psych. 15 (1904) 72-101
22. Stieber P, Dienemann H, Hasholzner U, Müller C, Poley S, Hofmann K, Fateh-Moghadam A: Comparison of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA) and tissue polypeptide specific antigen (TPS) as tumour markers in lung cancer. Eur. J. Clin. Chem. Clin. Biochem. 31 (1993) 689-694
23. Stieber P. Hasholzner U, Bodenmüller H, Nagel D, Sunder-Plassmann L, Dienemann H, Meier W, Fateh-Moghadam A: CYFRA 21-1. A new marker in lung cancer. Cancer 72 (1993) 707-713
24. Stieber P, Wollenberg B, Schmitt U M. von Jan N, Hofmann K, Fateh-Moghadam A: Stellenwert von Tumormarkern bei primä ren und rezidivierenden Plattenepithelkarzinomen des KopfHals-Bereiches. Tumordiagn. Ther. 17 (1996) 116-121
25. Strauss G M. Langer M P, Elias A D, Skarin A T, Sugarbaker D J: Multimodality treatment of stage IIIA non-small-cell lung carcinoma: a critical review of the literature and strategies for future research. J. Clin. Oncol. 10 (1992) 829-838
26. Strauss G M, Herndon J E, Sherman D D, Mathisen D J, Carey R W, Choi N C, Rege V B, Modeas C, Green M R: Neoadjuvant chemotherapy and radiotherapy followed by surgery in stage IIIA non-small-cell carcinoma of the lung: report of a Cancer and Leukemia Group B phase II study. J. Clin. Oncol. 10 (1992) 1237-1244
27. van der Gaast A, Schoenmakers C H H, Kok T C, Blijenberg B G, Cornillie F, Splinter T A W: Evaluation of a new tumour marker in patients with non-small-cell lung cancer: CYFRA 21-1. Br. J. Cancer 69 (1994) 525-528